Roland Solensky1, Joshua Jacobs2, Mitchell Lester3, Phillip Lieberman4, Frank McCafferty5, Thomas Nilsson6, Miguel Park7, Gavin Schwarz8, Weily Soong9, Amy Wagelie-Steffen10, H James Wedner11, Michael Weiss12, Hugh Windom13, James Tonascia14, Katherine P Yates14, Louis M Mendelson15, James Wolfe16, N Franklin Adkinson17. 1. The Corvallis Clinic and Oregon State University/Oregon Health & Science University College of Pharmacy, Corvallis, Ore. Electronic address: roland.solensky@corvallisclinic.com. 2. Allergy and Asthma Clinical Research, Inc, Walnut Creek, Calif. 3. Fairfield County Allergy, Asthma, and Immunology Associates, Norwalk, Conn. 4. University of Tennessee College of Medicine, Memphis, Tenn. 5. Atlanta Allergy and Asthma Research Section, Stockbridge, Ga. 6. Midwest Allergy and Asthma Clinic, Omaha, Neb. 7. Mayo Clinic, Rochester, Minn. 8. Connecticut Asthma & Allergy Center, West Hartford, Conn. 9. Clinical Research Center of Alabama and Alabama Allergy & Asthma Center, Birmingham, Ala. 10. Allergy Associates of Tucson, P.C., Tucson, Ariz. 11. The Asthma and Allergy Center of Washington University, St Louis, Mo. 12. Northwest Asthma and Allergy Center and University of Washington School of Medicine, Seattle, Wash. 13. University of South Florida, Tampa, Fla. 14. Johns Hopkins Bloomberg School of Public Health, Baltimore, Md. 15. University of Connecticut School of Medicine, Farmington, Conn; AllerQuest LLC, Plainville, Conn. 16. AllerQuest LLC, Plainville, Conn; Stanford University School of Medicine, Stanford, Calif; Allergy and Asthma Associates of Santa Clara Valley Research Center, San Jose, Calif. 17. AllerQuest LLC, Plainville, Conn; Johns Hopkins School of Medicine, Baltimore, Md.
Abstract
BACKGROUND: Ten percent of the population claims an allergy to penicillin, but 90% of these individuals are not allergic. Patients labeled as penicillin-allergic have higher medical costs, longer hospital stays, are more likely to be treated with broad-spectrum antibiotics, and develop drug-resistant bacterial infections. Most penicillin skin test reagents are not approved by the Food and drug Administration or readily available to evaluate patients labeled penicillin-allergic. OBJECTIVE: To determine the negative predictive value (NPV) of the Penicillin Skin Test Kit containing the major allergenic determinant (penicilloyl polylysine), a minor determinant mixture (penicillin G, penicilloate, penilloate), and amoxicillin, produced according to Food and Drug Administration standards. METHODS: This was a prospective, multicenter, open-label investigation of penicillin skin testing using the Penicillin Skin Test Kit. Skin test-negative subjects were challenged with 250 mg amoxicillin, whereas skin test-positive patients were not challenged. The primary end point was NPV of the Penicillin Skin Test Kit, defined as the percentage of subjects with negative skin test results who did not experience an IgE-dependent reaction within 72 hours of amoxicillin challenge. RESULTS: In total, 455 patients with a history of penicillin allergy underwent skin testing and 63 (13.8%) had 1 or more positive test results; 65% of the positive test results were to the minor determinant mixture and/or amoxicillin alone. In the per protocol group of 373 skin test-negative subjects, 8 developed potential IgE-dependent reactions following oral amoxicillin challenge, translating to an NPV of 97.9% (95% CI, 95.8-99.1; P < .0001). All but 1 of the reactions was mild or moderate, and most subjects who required treatment received only antihistamines. CONCLUSIONS: The Penicillin Skin Test Kit, containing all relevant penicillin allergenic determinants, demonstrated very high NPV. Removal of a penicillin allergy label in a large majority of currently mislabeled patients has substantial personal and public health implications.
BACKGROUND: Ten percent of the population claims an allergy to penicillin, but 90% of these individuals are not allergic. Patients labeled as penicillin-allergic have higher medical costs, longer hospital stays, are more likely to be treated with broad-spectrum antibiotics, and develop drug-resistant bacterial infections. Most penicillin skin test reagents are not approved by the Food and drug Administration or readily available to evaluate patients labeled penicillin-allergic. OBJECTIVE: To determine the negative predictive value (NPV) of the Penicillin Skin Test Kit containing the major allergenic determinant (penicilloyl polylysine), a minor determinant mixture (penicillin G, penicilloate, penilloate), and amoxicillin, produced according to Food and Drug Administration standards. METHODS: This was a prospective, multicenter, open-label investigation of penicillin skin testing using the Penicillin Skin Test Kit. Skin test-negative subjects were challenged with 250 mg amoxicillin, whereas skin test-positive patients were not challenged. The primary end point was NPV of the Penicillin Skin Test Kit, defined as the percentage of subjects with negative skin test results who did not experience an IgE-dependent reaction within 72 hours of amoxicillin challenge. RESULTS: In total, 455 patients with a history of penicillinallergy underwent skin testing and 63 (13.8%) had 1 or more positive test results; 65% of the positive test results were to the minor determinant mixture and/or amoxicillin alone. In the per protocol group of 373 skin test-negative subjects, 8 developed potential IgE-dependent reactions following oral amoxicillin challenge, translating to an NPV of 97.9% (95% CI, 95.8-99.1; P < .0001). All but 1 of the reactions was mild or moderate, and most subjects who required treatment received only antihistamines. CONCLUSIONS: The Penicillin Skin Test Kit, containing all relevant penicillin allergenic determinants, demonstrated very high NPV. Removal of a penicillinallergy label in a large majority of currently mislabeled patients has substantial personal and public health implications.
Authors: Cosby A Stone; Jason Trubiano; David T Coleman; Christine R F Rukasin; Elizabeth J Phillips Journal: Allergy Date: 2019-05-26 Impact factor: 13.146
Authors: Mary L Staicu; David Vyles; Erica S Shenoy; Cosby A Stone; Taylor Banks; Kristin S Alvarez; Kimberly G Blumenthal Journal: J Allergy Clin Immunol Pract Date: 2020-10
Authors: Kimberly G Blumenthal; Emily M Huebner; Xiaoqing Fu; Yu Li; Gita Bhattacharya; Amy S Levin; Christian M Mancini; Benjamin R Slawski; Aleena Banerji Journal: J Allergy Clin Immunol Pract Date: 2019-04-11
Authors: Anna R Wolfson; Christian M Mancini; Aleena Banerji; Xiaoqing Fu; Allison S Bryant; Neelam A Phadke; Erica S Shenoy; Weaam Arman; Yuqing Zhang; Kimberly G Blumenthal Journal: J Allergy Clin Immunol Pract Date: 2020-11-16
Authors: Jason A Trubiano; Sara Vogrin; Kyra Y L Chua; Jack Bourke; James Yun; Abby Douglas; Cosby A Stone; Roger Yu; Lauren Groenendijk; Natasha E Holmes; Elizabeth J Phillips Journal: JAMA Intern Med Date: 2020-05-01 Impact factor: 44.409